EnGene (ENGN) reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.

Analysts polled by FactSet expected a loss of $2.10.

Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.

Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.

The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.